Multidimensional analysis of the role of BRI3BP in the occurrence, development and prognosis of esophageal cancer

Background: The development of esophageal cancer (ESCA) is a complex biological process. An in-depth understanding of the possible pathogenesis mechanisms of ESCA and the identification of new effective biomarkers could improve diagnostic and treatment strategies for ESCA. Methods: To determine the differences in BRI3BP expression between tumor and normal tissue samples and the relationship between BRI3BP expression and clinical characteristics of ESCA patients, we assessed TCGA and GEO data. Results: The expression of the BRI3BP gene is significantly greater in tumor samples than in normal samples from ESCA patients in the TCGA and GEO (GSE5362, GSE23400, and GSE199967) cohorts. In addition, BRI3BP expression is a good predictor of the immunotherapeutic response in patients with ESCA. BRI3BP affects m6A modification in ESCA by regulating RBMX. BRI3BP may play an important role in cuproptosis in ESCA by regulating CDK5RAP1 and ultimately affecting the development and prognosis of ESCA. Furthermore, we predict that the MAPKAPK5-AS1−hsa-miR-145-5p−BRI3BP ceRNA network may play an important role in the development of ESCA. Conclusion: BRI3BP is a potential biomarker for ESCA diagnosis and treatment and is associated with immune infiltration, m6A modification, cuproptosis and the ceRNA regulatory network in ESCA.